XML 24 R12.htm IDEA: XBRL DOCUMENT
v3.25.3

Marketable Securities | 9 Months Ended
--- | ---
Sep. 30, 2025
Investments, Debt and Equity Securities [Abstract] |
Marketable Securities | Marketable Securities Restricted marketable securities at both balance sheet dates represent restricted assets held at HCS, Ltd (“HCS”), our consolidated wholly owned offshore captive insurance company. HCS insures a substantial portion of Encompass Health’s professional liability, workers’ compensation, and other insurance claims. These funds are committed for payment of claims incurred, and the classification of these marketable securities as current or noncurrent depends on the classification of the corresponding claims liability. As of September 30, 2025, $34.1 million of restricted marketable securities are included in Other current assets and $105.7 million of restricted marketable securities are included in Other long-term assets in our condensed consolidated balance sheet. As of December 31, 2024, $39.0 million of restricted marketable securities are included in Other current assets and $91.9 million are included in Other long-term assets in our condensed consolidated balance sheet. During the three and nine months ended September 30, 2025, $1.0 million and $1.8 million, respectively, of unrealized net gains (losses) were recognized in our condensed consolidated statements of operations on equity securities still held at the reporting date. During the three and nine months ended September 30, 2024, $2.8 million and $2.7 million, respectively, of unrealized net gains (losses) were recognized in our condensed consolidated statements of operations on equity securities still held at the reporting date. A summary of our debt securities as of September 30, 2025 is as follows (in millions):
| Amortized Cost |  | Gross Unrealized Gains |  |  |  | Fair Value
Available-for-sale debt securities: |  |  |  |  |  |  |
U.S. government and agency securities | $ | 44.6 |  |  | $ | 0.2 |  |  |  |  | $ | 44.8 |
Corporate bonds and notes | 58.9 |  |  | 0.4 |  |  |  |  | 59.3 |
During the three and nine months ended September 30, 2025, we did not record any impairment charges related to our debt securities. We did not have any debt securities during the three and nine months ended September 30, 2024. Investing information related to our available-for-sale debt securities is as follows (in millions):
| Three Months Ended September 30, |  | Nine Months Ended September 30,
| 2025 |  | 2024 |  | 2025 |  | 2024
Proceeds from sales and maturities | $ | 16.3 |  |  | $ | — |  |  | $ | 25.0 |  |  | $ | — |
The contractual maturities of our available-for-sale debt securities as of September 30, 2025 are as follows (in millions):
| Amortized Cost |  | Fair Value
Due in one year or less | $ | 23.9 |  |  | $ | 23.9 |
Due after one year through five years | 69.5 |  |  | 69.9 |
Due after five years through ten years | 4.7 |  |  | 4.8 |
Due after ten years | 5.4 |  |  | 5.5 |
Total | $ | 103.5 |  |  | $ | 104.1 |

X
- References No definition available. + Details
Name: | us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for investments in certain debt and equity securities. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 940 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/940-320/tableOfContent Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1403 -Paragraph b -Publisher SEC Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/320/tableOfContent Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/942-320/tableOfContent + Details
Name: | us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration